Acute HIV at the time of initiation of Pre or Post Exposure Prophylaxis: Impact on drug-resistance and clinical outcomes.

Although rare (occurring <0.5% of the time), AHI in the setting of PrEP/2-drug PEP can result in an M184 within days. Even with M184, persons with AHI achieve viral suppression when rapidly linked to care and initiated on antiretroviral therapy. Providers should consider AHI screening when starting PrEP/PEP.